Wogonoside (Synonyms: Wogonin 7-β-D-Glucuronide, Wogonin 7-O-β-D-Glucuronide) |
Catalog No.GN10097
One-Click Copy Product Info
|
Wogonoside is a naturally occurring flavone glucuronide that inhibits α-glucosidase with an IC50 value of18.25nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51059-44-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Wogonoside is a naturally occurring flavone glucuronide that inhibits α-glucosidase with an IC50 value of 18.25nM[1]. Wogonoside suppresses inflammatory responses by inhibiting macrophage pyroptosis through blockade of the NOD-like receptor family pyrin domain containing 3 (NLRP3)/caspase-1/gasdermin D signaling cascade and modulation of purinergic signaling[2]. Wogonoside exhibits a variety of biological activities, such as anti-inflammatory, lipid-lowering and cardiac function improvement effects, and is widely used to mitigate atherosclerosis[3].
In vitro, Wogonoside treatment for 48 hours significantly inhibited the viability of U251MG, SHG44, A172 and U87MG cells, with IC50 values of 193.44μM, 305.08μM, 269.54μM and 199.83μM, respectively[4]. Incubation of RAW264.7 cells with 50μM Wogonoside for 24 hours reduced lipopolysaccharides (LPS)-induced the production of NO and PGE2, and decreased the levels of TNF-α and IL-6[5].
In vivo, Wogonoside treatment via oral administration at a dose of 8mg/kg daily for 4 weeks alleviated CCl4-elicited liver fibrosis in rats, and effectively restored the levels of superoxide dismutase, glutathione and IL-10[6]. Oral administration of Wogonoside (50mg/kg/day) for 10 consecutive days alleviated the dextran sulfate sodium (DSS)-caused colitis in mice, improved intestinal barrier function and regulated bacterial translocation[7]. Intragastric administration of Wogonoside at a dose of 40mg/kg daily for 8 weeks inhibited the progression of osteoarthritis in a mouse model of destabilization of the medial meniscus (DMM), reduced proteoglycan loss, and attenuated cartilage calcification[8].
References:
[1] Zeng X, Zhao M, Yao H. Anti-lung cancer, anti-microbial, anti-α-glucosidase, anti-sorbitol dehydrogenase, and in silico studies of wogonoside and isoliquiritigenin as natural compounds[J]. Journal of Oleo Science, 2023, 72(10): 919-927.
[2] Ni H T N, Huan D Q, Vu H D, et al. Wogonoside: Chemistry, pharmacology, and pharmacokinetics[J]. Fitoterapia, 2026: 107354.
[3] Gong Z, Yang H, Gao L, et al. Mechanisms of wogonoside in the treatment of atherosclerosis based on network pharmacology, molecular docking, and experimental validation[J]. BMC Complementary Medicine and Therapies, 2025, 25(1): 28.
[4] Zhang L, Wang H, Cong Z, et al. Wogonoside induces autophagy-related apoptosis in human glioblastoma cells[J]. Oncology Reports, 2014, 32(3): 1179-1187.
[5] Yang Y Z, Tang Y Z, Liu Y H. Wogonoside displays anti-inflammatory effects through modulating inflammatory mediator expression using RAW264. 7 cells[J]. Journal of Ethnopharmacology, 2013, 148(1): 271-276.
[6] Wang Q, Wen R, Lin Q, et al. Wogonoside shows antifibrotic effects in an experimental regression model of hepatic fibrosis[J]. Digestive Diseases and Sciences, 2015, 60(11): 3329-3339.
[7] Huang S, Fu Y, Xu B, et al. Wogonoside alleviates colitis by improving intestinal epithelial barrier function via the MLCK/pMLC2 pathway[J]. Phytomedicine, 2020, 68: 153179.
[8] Tang Q, Zheng G, Feng Z, et al. Wogonoside inhibits IL-1β induced catabolism and hypertrophy in mouse chondrocyte and ameliorates murine osteoarthritis[J]. Oncotarget, 2017, 8(37): 61440.
| Cell experiment [1]: | |
|
Cell lines |
A172 cells |
|
Preparation Method |
A172 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, and 1% penicillin/streptomycin at 37°C in an incubator with 5% CO2. Cells (5×103/well) were seeded in the 96-well plates and cultivated for 24h to adhere. After treatment with different concentrations of Wogonoside (0, 100, 200, 300, 400, and 500μM) for 48h, cell viability was measured. |
|
Reaction Conditions |
0, 100, 200, 300, 400, and 500μM; 48h |
|
Applications |
Wogonoside treatment reduced cell viability in A172 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male Wistar rats |
|
Preparation Method |
Male Wistar rats were kept in an air-conditioned room at 23±2°C with a 12h light/dark cycle. The rats were randomly divided into 3 groups (n=10): the control group, the CCl4 group (model group), the CCl4 and Wogonoside (8mg/kg/day) group. Hepatic fibrosis was induced by subcutaneous injection of CCl4 (1:1 in olive oil) in rats at a dose of 3ml/kg twice-weekly for consecutive 6 weeks. The rats in the control group were injected with an equal volume of olive oil without CCl4. When the hepatic fibrosis model was established and identified, the rats in the Wogonoside groups received 8mg/kg Wogonoside (p.o.) dissolved in normal saline daily for consecutive 4 weeks. Accordingly, rats in the control and model groups received an equal volume of normal saline. The body weights of all rats were recorded once a week. At the end of the experimental period, the rats were anesthetized with 20% urethane, and then killed. The livers were immediately harvested for analysis. |
|
Dosage form |
8mg/kg/day; 4 weeks; p.o. |
|
Applications |
Wogonoside treatment attenuated CCl4-induced hepatic fibrogenesis and prevented weight loss in rats. |
References: [1] Zhang L, Wang H, Cong Z, et al. Wogonoside induces autophagy-related apoptosis in human glioblastoma cells[J]. Oncology Reports, 2014, 32(3): 1179-1187. [2] Wang Q, Wen R, Lin Q, et al. Wogonoside shows antifibrotic effects in an experimental regression model of hepatic fibrosis[J]. Digestive Diseases and Sciences, 2015, 60(11): 3329-3339. | |
| Cas No. | 51059-44-0 | SDF | |
| Synonyms | Wogonin 7-β-D-Glucuronide, Wogonin 7-O-β-D-Glucuronide | ||
| Chemical Name | (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(5-hydroxy-8-methoxy-4-oxo-2-phenylchromen-7-yl)oxyoxane-2-carboxylic acid | ||
| Canonical SMILES | COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)OC4C(C(C(C(O4)C(=O)O)O)O)O | ||
| Formula | C22H20O11 | M.Wt | 460.4 |
| Solubility | DMF: 5mg/mL,DMSO: 15mg/mL,PBS (pH 7.2): 2mg/mL | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.172 mL | 10.8601 mL | 21.7202 mL |
| 5 mM | 434.4 μL | 2.172 mL | 4.344 mL |
| 10 mM | 217.2 μL | 1.086 mL | 2.172 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)